Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib

Neurology. 2014 Oct 14;83(16):1478-80. doi: 10.1212/WNL.0000000000000880. Epub 2014 Sep 10.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / genetics
  • Central Nervous System Neoplasms / metabolism
  • Central Nervous System Neoplasms / pathology
  • Fatal Outcome
  • Histiocytic Sarcoma / drug therapy*
  • Histiocytic Sarcoma / genetics
  • Histiocytic Sarcoma / metabolism
  • Histiocytic Sarcoma / pathology
  • Humans
  • Indoles / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Point Mutation*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Proto-Oncogene Proteins B-raf / metabolism
  • Sulfonamides / therapeutic use*
  • Treatment Outcome
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf